- Home
- DXR vs TENX Comparison
DXR vs TENX Comparison
Compare DXR & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | TENX |
|---|---|---|
| Founded | 1970 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 56.2M |
| IPO Year | 1995 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DXR | TENX |
|---|---|---|
| Price | $10.61 | $14.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 9.9K | ★ 543.2K |
| Earning Date | 02-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.10 | $5.34 |
| 52 Week High | $14.76 | $18.38 |
Technical Indicators
Market Signals| Indicator | DXR | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 73.84 | 50.93 |
| Support Level | $12.12 | $12.84 |
| Resistance Level | $14.02 | $16.61 |
| Average True Range (ATR) | 0.50 | 1.02 |
| MACD | 0.32 | -0.03 |
| Stochastic Oscillator | 100.00 | 47.48 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.